

November 18, 2016

U.S. Nuclear Regulatory Commission, Region III  
Attn: Materials Licensing Section  
2443 Warrenville Rd.  
Suite 210  
LISLE, IL 60532-4352

RE: NRC License #21-04515-01


Event #: TBD (Previously reported by telephone on 11/18/16 under 10 CFR 35.3067.

It was reported an I-125 seed in a breast tissue specimen had been damaged during extraction from the specimen. Following is a follow up written report in compliance with 10 CFR 35.3067.

- (i) **Licensed Material:** Quantity: 1  
Type: I-125, solid sealed (encapsulated in Tungsten), 4.5 mm Long and 0.5mm diameter  
Strength: 0.196 mCi
- (ii) **Description of circumstances:** Pathology received a breast tissue specimen containing a single  $^{125}\text{I}$  seed. In the process of preparing the specimen, when the seed was extracted, it was found to be half a seed. The second half of the seed was removed from the specimen and both halves were placed in a plastic vial with a cap. The vial was then placed in a lead pouch and placed in the radioactive storage cupboard. An area survey was conducted with negative results. Wipe tests were performed and the area decontaminated. The source was taken from the pathology radioactive storage cupboard to decay in storage in the radiation oncology hot lab.
- (iii) One  $^{125}\text{I}$  seed was implanted into a patient. The seed had a written directive which accompanied the seed. After implantation, the patient went to surgery where the seed was removed. In addition to the placement of the  $^{125}\text{I}$  seed, the patient also underwent a lymphoscintigraphy procedure.
- (iv) Radiographs of the tissue sample obtained in the operating room indicate the seed was present and intact within the tissue specimen when removed from the patient.
- (v) Radiographs of the tissue sample after removal of the two seed halves indicate the entire seed was removed from the tissue specimen.
- (vi) The damaged radioactive seed will be held for decay in the radiation oncology hot lab.
- (vii) The tissue specimen will be stored and processed per hospital procedure for the processing of radioactive tissue from lymphoscintigraphy.
- (viii) Contaminated pathology tools and equipment will be cleaned and returned or held until decayed and disposed.
- (ix) A Thyroid bioassay was performed on the pathology technician working with the specimen and the results were negative.
- (x) It is our conclusion that no one received or will receive any additional exposure due to the radioactive seed being damaged.

If you have any questions, please contact Lisa Benedetti @248-551-7072 or 248-420-2390 or [lisa.benedetti@beaumont.org](mailto:lisa.benedetti@beaumont.org). We appreciate your prompt attention to this matter.

Sincerely,



Lisa Benedetti,  
Director Clinical Physics  
Oakwood Hospital and Medical Center  
18101 Oakwood Blvd.  
Dearborn, MI 48123

RECEIVED NOV 30 2016

# Beaumont

Beaumont Hospital, Dearborn  
Radiation Oncology  
18101 Oakwood Blvd.  
Dearborn, MI 48124

RETURN  
RECEIPT REQUESTED

11742022

CERTIFIED MAIL



7015 1520 0000 9374 9906



U.S. POSTAGE >> PITNEY BOWES



ZIP 48073 \$ 006.46<sup>5</sup>  
02 1W  
0001403132 NOV 21 2016

U.S. Nuclear Regulatory Commission, Region III  
Attn: Materials Licensing Section  
2443 Warrenville Rd  
Suite 210  
Lisle, IL 60532-4352

RECEIVED NOV 30 2016

605324352 C021

